

A.1 Contents GMP Regulations

A Information

- A.1 Contents GMP Regulations
- A.2 Index GMP Regulations
- A.3 List of Abbreviations
- A.4 Glossary
- A.5 Adress-Register
- A.6 References

B Japanese Regulations

- B.1 MHW Ministerial Ordinance No. 2,1961:
Regulations for Buildings and Facilities of Pharmacies, etc.
- B.2 MHLW Ministerial Ordinance No. 136,2004 :
Standards for Quality Assurance for Drugs, Quasi-drugs, Cosmetics and Medical Devices
- B.3 MHLW Ministerial Ordinance No. 179, 2004:
Standards for Manufacturing Control and Quality Control for Drugs and Quasi-drugs

C EU GMP Guide

- C.1 Introduction
- C.2 Commission Directive 2003/94/EC
- C.3 Directive 91/412/EEC
- C.4 Part I
Basic Requirements for Medicinal Products
- C.5 Part II
Basic Requirements for Active Substances used as Starting Materials
- C.6.1 Annex 1
Manufacture of Sterile Medicinal Products
- C.6.2 Annex 2
Manufacture of Biological Medicinal Products for Human Use
- C.6.3 Annex 3
Manufacture of Radiopharmaceuticals
- C.6.4 Annex 4
Manufacture of Veterinary Medicinal Products other than Immunological Veterinary Medicinal Products
- C.6.5 Annex 5
Manufacture of Immunological Veterinary Medicinal Products

- A.1**
- C.6.6 Annex 6
Manufacture of Medicinal Gases
 - C.6.7 Annex 7
Manufacture of Herbal Medicinal Products
 - C.6.8 Annex 8
Sampling of Starting and Packaging Materials
 - C.6.9 Annex 9
Manufacture of Liquids, Creams and Ointments
 - C.6.10 Annex 10
Manufacture of Pressurised Metered Dose Aerosol Preparations for Inhalation
 - C.6.11 Annex 11
Computerised Systems
 - C.6.12 Annex 12
Use of Ionising Radiation in the Manufacture of Medicinal Products
 - C.6.13 Annex 13
Manufacture of Investigational Medicinal Products
 - C.6.14 Annex 14
Manufacture of Medicinal Products Derived from Human Blood or Plasma
 - C.6.15 Annex 15
Qualification and Validation
 - C.6.16 Annex 16
Certification by a Qualified Person and Batch Release
 - C.6.17 Annex 17
Parametric Release
 - C.6.18 Annex 18
Good Manufacturing Practice for Active Pharmaceutical Ingredients
 - C.6.19 Annex 19
Reference Samples and Retention Samples
 - C.6.20 Annex 20:
Quality Risk Management
 - C.7 Glossary
 - C.8 Index EU GMP Guide C.1 to C.6.20
 - C.9 Note For Guidance on Quality of Water for Pharmaceutical Use
 - C.9 Index C.9
 - C.10 Compilation of Community Procedures on Inspections and Exchange of Information

D USA: CFR and FDA Guidelines

- D.1 Code of Federal Regulations
- D.1 Index chapter D.1
- D.2 Guideline on General Principles of Process Validation
- D.2 Index chapter D.2
- D.3 Guide to Inspections of High Purity Water Systems
- D.3 Index chapter D.3

- D.4 Guide to Inspections of Validation of Cleaning Processes
- D.4 Index chapter D.4
- D.5 Guide to inspections of oral solid dosage forms pre/post approval issues for development and validation
- D.5 Index chapter D.5
- D.6 Guide to Inspections of Validation Documentation
- D.6 Index chapter D.6
- D.7 Guide to Inspections:
Computerized Systems in Drug Establishments (2/83)
- D.7 Index chapter D.7
- D.8 Guide to Inspections of Pharmaceutical Quality Control Laboratories
- D.8 Index chapter D.8
- D.9 Guidance for Industry:
Investigating Out-of-Specification (OOS)
Test Results for Pharmaceutical Production
- D.9 Index chapter D.9
- D.10 Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing – Current Good
Manufacturing Practice
- D.10 Index chapter D.10
- D.11 Guidance for Industry
PAT – A Framework for Innovative Pharmaceutical Development,
Manufacturing, and Quality Assurance
- D.11 Index chapter D.11
- D.12 Guidance for Industry
Part 11, Electronic Records; Electronic Signatures – Scope and Application
- D.12 Index chapter D.12
- D.13 21 CFR Part 820 – Quality System Regulation
- D.13 Index chapter D.13
- D.14 Guidance for Industry
Quality Systems Approach to Pharmaceutical CGMP Regulations
- D.14 Index chapter D.14
- D.15 Guidance for Industry
CGMP for Phase 1 Investigational Drugs
- D.16 Federal Food, Drug, and Cosmetic Act (FD&C Act)

- E ICH-Guidelines**
- E.1.A ICH Q1A(R2):
Stability Testing of New Drug Substances and Products
- E.1.B ICH Q1B:
Stability Testing: Photostability Testing of New Drug Substances and Products
- E.1.C ICH Q1C:
Stability Testing for New Dosage Forms

- E.1.D ICH Q1D:
Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
- E.1.E ICH Q1E:
Evaluation of Stability Data
- E.1.F ICH Q1F:
will be published in one of the following updates.
- E.1 Index ICH Q1
- E.2 ICH Q2(R1):
Validation of Analytical Procedures:
Text and Methodology
- E.2 Index ICH Q2(R1)
- E.3.A ICH Q3A(R2):
Impurities in New Drug Substances
- E.3.B ICH Q3B(R2):
Impurities in New Drug Products
- E.3.C ICH Q3C(R3):
Guideline for Residual Solvents
- E.3 Index ICH Q3
- E.4 ICH Q4:
Pharmacopoeias
- E.4.A ICH Q4A:
Pharmacopoeial Harmonisation
- E.4.B ICH Q4B:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
- E.4.B.1 ICH Q4B Annex 1:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Residue on Ignition/Sulphated Ash
– General Chapter
- E.4.B.2 ICH Q4B Annex 2:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Extractable Volume of Parenteral Preparations
– General Chapter
- E.4.B.3 ICH Q4B Annex 3:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Test for Particulate Contamination: Sub-Visible Particles
– General Chapter
- E.4.B.4.1 ICH Q4B Annex 4A:
Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
Microbiological Examination of Non-Sterile Products:
Microbial Enumerations Tests
General Chapter

- E.4.B.4.2 ICH Q4B Annex 4B :
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Microbiological Examination of
Non-Sterile Products: Test for Specified Micro-Organisms
General Chapter
- E.4.B.4.3 ICH Q4B Annex 4C:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Microbiological Examination of
Non-Sterile Products: Acceptance Criteria For Pharmaceutical
Preparations and Substances for Pharmaceutical Use
General Chapter
- E.4.B.5 ICH Q4B Annex 5:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Disintegration Test
General Chapter
- E.4.B.6 ICH Q4B Annex 6:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Uniformity of Dosage Units
General Chapter
- E.4.B.7 ICH Q4B Annex 7:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Dissolution Test
General Chapter
- E.4.B.8 ICH Q4B Annex 8:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Sterility Test
General Chapter
- E.4.B.9 ICH Q4B Annex 9:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Tablet Friability
General Chapter
- E.4.B.10 ICH Q4B Annex 10:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Polyacrylamide Gel Electrophoresis
General Chapter
- E.4 Index ICH Q4
- E.5.A ICH Q5A(R1):
Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of
Human or Animal Origin
- E.5.B ICH Q5B:
Quality of Biotechnological Products: Analysis of the Expression Construct in
Cells Used for Production of R-DNA Derived Protein Products
- E.5.C ICH Q5C:
Quality of Biotechnological Products: Stability Testing of Biotechnological/
Biological Products

- A.1**
- E.5.D ICH Q5D:
Derivation and Characterisation of Cell Substrates used for Production of Biotechnological/Biological Products
 - E.5.E ICH Q5E:
Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process
 - E.5 Index ICH Q5
 - E.6.A ICH Q6A:
Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
 - E.6.B ICH Q6B:
Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
 - E.6 Index ICH Q6
 - E.7 ICH Q7:
Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
"How to do" Document – Interpretation of the ICH Q7a Guide
 - E.7.1 Index ICH Q7
 - E.8 ICH Q8 (R1):
Pharmaceutical Development
 - E.8 Index ICH Q8 (R1)
 - E.9 ICH Q9:
Quality Risk Management
 - E.9 Index ICH Q9
 - E.10 ICH Q10:
Pharmaceutical Quality System
 - E.10 Index ICH Q10

F PIC/S Guidelines

- F.1 PIC/S PI 006-3:
Recommendations on Validation Master Plan
Installation and Operational Qualification
Non-Sterile Process Validation
Cleaning Validation
Index chapter F.1
- F.2 PIC/S PI 007-5:
Recommendation on the Validation of Aseptic Processes
Index chapter F.2
- F.3 PIC/S PI 011-3:
PIC/S Guidance
Good Practices for Computerised Systems in Regulated "GXP" Environments
Index chapter F.3

- F.4 PIC/S PI 023-2:
Aide-Memoire
Inspection of Pharmaceutical Quality Control Laboratories
- F.4 Annex to PIC/S PI 023-2:
Aide-Memoire
for Inspections of Pharmaceutical Quality Control Laboratories
- F.4 Index chapter F.4
- F.5 PIC/S PE 008-3:
Explanatory Notes for Industry on the Preparation of a Site Master File
- F.5 Index chapter F.5
- F.6 PIC/S PI 009-3:
Aide mémoire
Inspection of Utilities
- F.6 Index chapter F.6

G GMP of other Regions

This chapter is supplied on CD-ROM and online (www.GMP-MANUAL.com) only.

H Empty Register

This chapter is left empty in order to facilitate later additions.

